Both the World Health Organization (WHO) and US Centers for Disease Control (CDC) have recommended (provisionally) that bedaquiline be reserved for patients with multidrug-resistant tuberculosis when an otherwise recommended regimen cannot be designed [REF].
Small studies have also examined its use as salvage therapy for non-tuberculous mycobacterial infections [REF].